For the chart of the week we wanted to explore the market for multi-analyte panels. We found that single biomarker tests still vastly outnumber panels. Stay tuned for more trending information in the coming weeks. My hypothesis: Panels, even outside of NGS, are being introduced to the market faster than single biomarker tests.
Share this Image On Your Site
<p><strong>Please include attribution to amplion.com with this graphic.</strong><br /><br /><a href=’https://amplion.wpengine.com/biomarker-trends/chart-of-the-week-panel-still-emerging-single-biomarker-tests-dominate’><img src=’https://amplion.com/wp-content/uploads/2016/06/TestBiomarkerCounts-1.png’ alt=’Biomarker Counts in Diagnostic Tests’ width=’540px’ border=’0′ /></a></p>
For a refresher on Amplion and BiomarkerBase:
[plsc_button url=”https://amplion.wpengine.com/biomarkerbase-demo/?hsCtaTracking=f9d217c0-3d3d-4625-adcc-7be5c13cb9be%7C379a477c-1ce0-462d-87d0-ff5cadcfa342″ target=”_blank” color=”green” style=”flat” radius=”square” size=”lg”]REQUEST DEMO[/plsc_button]